News from Bayer
August 03, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
July 29, 2021
Bayer Provides Update on Path to Closure of Roundup™ Litigation
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU